



Exploring Study on Genome Editing Tools

Sohib Khan¹, Sonali Katiyar², Sneha Singh³, Ravi kumar⁴, Dr. Nakul Gupta⁵

^{1,2,3}Research scholar IIMT College Of Pharmacy, Greater Noida

⁴Asst.professor of pharmaceutical chemistry IIMT College of pharmacy

⁵Director of IIMT College of Pharmacy

ABSTRACT

In classical genetics, the gene- modifying conditioning were carried out opting inheritable spots related to the breeder's thing. latterly, scientists used radiation and chemical mutagens to increase the probability of inheritable mu tations in experimental organisms. Although these styles were slight useful as they were time- consuming and Not Pocket friendly. In this comprehensive review, we bandy the progression of mileposts leading to the emergence of the clustered regularly interspaced short palindromic reprises(CRISPR)- grounded technology as a important tool for precise and targeted variations of the mortal genome. CRISPR- Cas9 nuclease, base editing, and high editing have taken center stage, demonstrating remarkable perfection and efficacy in targeted ex vivo and in vivo genomic variations. Enhanced delivery systems, including viral vectors and nanoparticles, have further bettered the effectiveness and safety of remedial gene editing, advancing their clinical translatability. The disquisition of CRISPR- Cas systems beyond the generally used Cas9, similar as the development of Cas12 and Cas13 variants, has expanded the force of gene editing tools, enabling further intricate variations and remedial interventions. Outstandingly, high editing represents a significant vault forward, given its unequaled versatility and minimisation of out-target goods. These inventions have paved the way for remedial gene editing in a multitude of preliminarily incorrigible inheritable diseases, ranging from monogenic conditions to complex polygenic conditions. This review highlights the rearmost innovative studies in the field, emphasising

advance technologies in pre-clinical and clinical trials, and their operations in the realm of perfection drug. still, Challenges are faced to continue the exploration to upgrade safety biographies and ethical fabrics.

Keywords: CRISPR-Cas9 TALENs Zinc Finger Nucleases Base Editing Prime Editing

How to Cite this Article:

Khan, S., Katiyar, S. & Singh, S. (2026). Exploring Study on Genome Editing Tools. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(05). <https://doi.org/10.55041/ijcope.v2i5.032>

License:

This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

© The Author(s). Published by International Journal of Creative and Open Research in Engineering and Management.




<https://doi.org/10.55041/ijcope.v2i5.032>



INTRODUCTION

Genome Editing or Genome manipulation of inheritable material is n't a fully New ultramodern conception; The sweats in this field can be tracked back to the 1970s. Early Age investigators done the root for contemporary genome engineering by exploring possibilities aimed at achieving controlled and point-specific inheritable changes(36,59). A vital advancement passed when it was demonstrated that a DNA construct adjoined by sequences homologous to a target locus could integrate into the host genome through homologous recombination(HR). This discovery successfully handed a medium for introducing precise and predetermined inheritable variations(10). Far piecemeal from this progress, the exclusive dependence on(HR) posed several specialized obstacles. The rate of successful integration of exogenous DNA into the intended genomic point was slightly and generally Low, and arbitrary insertion events at unintended locales were constantly reported in the natural Reports. similar limitations compromised with delicacy and effectiveness of early gene Editing approaches, emphasizing the necessity for further dependable and controllable genome- editing technologies. latterly studies revealed that finagled DNA restriction enzymes can be introduced into cells to induce double- stranded DNA(dsDNA) & breaks at specific recognition sequences. The induction of these targeted breaks activates natural cellular form mechanisms, primarily homologous recombination(HR) and non-homologous end joining(NHEJ), thereby significantly perfecting the effectiveness of genome revision(14). As a result, numerous ultramodern gene- editing methodologies have been developed around programmable endonuclease platforms able of producing precise double-beachfront breaks at defined genomic spots(53,78) point-specific nucleases serve by feting particular DNA sequences and introducing controlled fractionalization through their catalytic exertion. The performing DNA breaks stimulate endogenous form pathways basically HR and NHEJ which grease the preface of targeted inheritable differences.





1.1. Early Gene Editing Technologie

The discovery of restriction enzymes are covered from further than five decades ago marked the morning of ultramodern gene editing approaches(4). These enzymes fete specific DNA sequences and introduce cuts at compactly defined locales, enabling controlled revision of inheritable material. Their operation deposited the foundation for recombinant DNA technology, which made it possible to slice and transfer genes between different organisms. piecemeal their significance, restriction endonucleases retain fixed recognition sequences that can not be reproached. This limitation absoutely restricts their inflexibility, as suitable fractionalization spots may not be present near the intended genomic target. sweats to develop more flexible tools for generating targeted double-beachfront breaks(DSBs) led to the emergence of finagled nucleases, beginning with zinc cutlet nucleases(ZFNs). ZFNs were created by fusing customizable zinc cutlet DNA-binding disciplines to the nonspecific fractionalization sphere of the type IIS restriction enzyme FokI, firstly deduced from Flavobacterium okeanokoites(5). posterior studies demonstrated that FokI requires dimerisation to induce DNA fractionalization, with each monomer cutting a single DNA beachfront to produce a DSB(6). Because zinc cutlet modules can be finagled to fete specific DNA triumvirates, ZFNs enabled targeted gene revision, including correction of mutations in the IL2RG gene associated with severe combined immunodeficiency(SCID)(7). This represented a major step forward in precise genome manipulation. Shortly later, recap activator- suchlike effector nucleases(TALENs) were introduced as another class of FokI- grounded finagled nucleases, deduced from Xanthomonas species(8). TALENs offered bettered design inflexibility due to their modular reprise disciplines, which are generally easier to assemble compared to zinc cutlet arrays. also, TALENs tend to parade lower off- target fractionalization rates. still, both ZFNs and TALENs bear expansive protein engineering, cloning, and assembly for each new genomic target, making the process labor-ferocious and limiting their scalability.

1.2. The Emergence of CRISPR-Cas9

Atransformative advancement in programmable genome editing passed with the identification of the CRISPR- Cas system, particularly the RNA- guided endonuclease Cas9 from Streptococcus pyogenes(9). In discrepancy to earlier protein- grounded targeting systems, CRISPR- Cas9 relies on a customizable single- companion RNA(sgRNA) to direct DNA fractionalization at specific genomic spots. The targeting particularity is determined by the sequence of the RNA, which can be fluently synthesized and modified(Figure 1A). Unlike FokI-dependent systems, Cas9 does n't bear dimerization for exertion, as it contains two natural nuclease disciplines the HNH sphere, which cleaves the DNA beachfront reciprocal to the companion RNA, and the RuvC- suchlike sphere, which cuts thenon-complementary beachfront(9). The simplicity, effectiveness, and rigidity of CRISPR- Cas9 have been validated across multitudinous organisms, including mortal cells(10 – 12). likewise, the ease of designing multiple sgRNAs has enabled the development of genome-wide sgRNA libraries, easing high- outturn functional inheritable webbing and expanding the compass of gene- editing exploration(12,13).

CRISPR-Cas systems

Theseare the adaptiveimmune mechanisms naturally present in bacteria and archaea to protect them against harmful genetic elements such as viruses (bacteriophages) and plasmids. The Term **CRISPR** stands for clustered regularly interspaced short palindromic reports , which refers to the specific repetitive DNA sequences found in prokaryotic genomes. These repetitions are associated with **CAS** (CRISPR-associated) Proteins. The archetypical Cas9 protein originating from Streptococcus pyo genes (SpCas9), the first Cas nuclease to be repurposed for genome editing, remains the most widely used gene editor due to its intrinsically high activity and specificity.

CRISPR nuclease-based genome editing :

The programmability ofCRISPR-Cas nucleases to generate site specific double-strand DNA breaks has enabled their rapid adaptation for genome editing technologies.

The CAS9 Forms an active nuclease in association with either crRNA-tracrRNA complexes or sgRNA Guides. (12,18) .

To direct the Cas9 nuclease to the genomic locus of interest, the 20-nt guide sequence on the 50 end of the crRNA can be altered to enable canonical base pairing with the DNA target. Target binding is additionally dependent on the presence of a short protospacer adjacent motif (PAM) located on the non-target strand (NTS) of the DNA,(11,12) immediately downstream of the target site.



CRISPR genome editing relies on RNA-guided nucleases such as Cas9 and Cas12a for site specific target DNA

recognition and cleavage. Cas9 utilizes a dual-guide RNA composed of a CRISPR RNA (crRNA)-trans-activating CRISPR RNA (tracrRNA) pair or a single-guide RNA (sgRNA), whereas Cas12a is programmed with a crRNA only. Target DNA recognition is dependent on complementarity with the spacer sequence of the guide RNA as well as the presence of a protospacer adjacent motif (PAM). Cas9 recognizes an NGG PAM, whereas Cas12a requires a TTTV PAM (V = G, C, or A). Upon target binding, the nucleases catalyze DNA cleavage, generating a DNA double-strand break (DSB). DSB repair by cellular DNA repair pathways leads to the introduction of genetic modifications (edits). The end joining pathways result in short insertions or deletions (indels), whereas homology-directed repair (HDR) using an exogenous DNA repair template can be used to engineer precise modifications.

Cas9 subsequently cleaves the double-stranded DNA (dsDNA) substrate three nucleotides upstream of the PAM sequence, generating DSBs with either blunt ends or single-nucleotide 5' overhangs (19-21). Selective inactivation of either nuclease domain converts Cas9 into RNA-guided nickases, whereas inactivation of both domains results in an RNA-guided DNA binding protein that can serve as a platform for delivery of fused proteins to specific genomic loci.5,12

Development of Next-Generation CRISPR-Cas9

Since Cas9 contains two nuclease domains, each cleaving one strand of DNA, point mutations have been introduced in the corresponding catalytic residues, i.e., D10A in RuvC, or H840A in HNH, to convert Cas9 into a DNA nickase (Cas9n) [9,10,12].

Since Cas9n cuts only one strand, two offset sgRNAs in proximity and on opposite strands are needed to create a DSB, thereby extending the number of required matching nucleotides. As individual nicks are repaired with high fidelity, this approach has significantly reduced the possibility of off-target damage. For example, Cas9n-D10A has been shown to be particularly efficient in minimizing off-target indels in cell lines and mouse zygotes [30]. The efficiency and high fidelity of this dual-nickase system has also been confirmed in various gene modification and knockout experiments [31–36].

To direct the Cas9 nuclease to the genomic locus of interest, the 20-nt guide sequence on the 5' end of the crRNA can be altered to enable canonical base pairing with the DNA target. Target binding is additionally dependent on the presence of a short protospacer adjacent motif (PAM) located on the non-target strand (NTS) of the DNA, (11,12) immediately downstream of the target site.

CRISPR genome editing relies on RNA-guided nucleases such as Cas9 and Cas12a for site specific target DNA

recognition and cleavage. Cas9 utilizes a dual-guide RNA composed of a CRISPR RNA (crRNA)-trans-activating CRISPR RNA (tracrRNA) pair or a single-guide RNA (sgRNA), whereas Cas12a is programmed with a crRNA only. Target DNA recognition is dependent on complementarity with the spacer sequence of the guide RNA as well as the presence of a protospacer adjacent motif (PAM). Cas9 recognizes an NGG PAM, whereas Cas12a requires a TTTV PAM (V = G, C, or A). Upon target binding, the nucleases catalyze DNA cleavage, generating a DNA double-strand break (DSB). DSB repair by cellular DNA repair pathways leads to the introduction of genetic modifications (edits). The end joining pathways result in short insertions or deletions (indels), whereas homology-directed repair (HDR) using an exogenous DNA repair template can be used to engineer precise modifications.

Cas9 subsequently cleaves the double-stranded DNA (dsDNA) substrate three nucleotides upstream of the PAM sequence, generating DSBs with either blunt ends or single-nucleotide 5' overhangs (19-21). Selective inactivation of either nuclease domain converts Cas9 into RNA-guided nickases, whereas inactivation of both domains results in an RNA-guided DNA binding protein that can serve as a platform for delivery of fused proteins to specific genomic loci.5,12

Development of Next-Generation CRISPR-Cas9



Since Cas9 contains two nuclease domains, each cleaving one strand of DNA, point mutations have been introduced in the corresponding catalytic residues, i.e., D10A in RuvC, or H840A in HNH, to convert Cas9 into a DNA nickase (Cas9n) [9,10,12].

Since Cas9n cuts only one strand, two offset sgRNAs in proximity and on opposite strands are needed to create a DSB, thereby extending the number of required matching nucleotides. As individual nicks are repaired with high fidelity, this approach has significantly reduced the possibility of off-target damage. For example, Cas9n-D10A has been shown to be particularly efficient in minimizing off-target indels in cell lines and mouse zygotes [30]. The efficiency and high fidelity of this dual-nickase system has also been confirmed in various gene modification and knockout experiments [31–36].

Base editing (BE) represents an innovative approach in which Cas9n is fused to a deaminase enzyme responsible for the direct conversion of one DNA base pair into another.

For example, cytosine base editors (CBEs) trigger C-to-T transition [37], adenine base editors (ABEs) trigger A-to-G transition [38], while others can trigger both simultaneously [39], or even C-to-G, C-to-A, and A-to-C transversions [40–44] (Figure 1C). BE has promptly proven its potential for in vivo correction of different pathogenic mutations associated with various diseases, as described below. By avoiding DSBs, BE prevents the risks of unintended indels. However, while BE is a powerful genome editing tool, it does have certain limitations and challenges. For example, the deaminase enzyme in base editors often has a specific editing window, or range of a few nucleotides, where it can effectively modify the target base. Consequently, it may also edit nearby bases within this window, leading to unintended mutations called “bystander” edits. Despite the fact that BE is designed to be highly specific, it may also induce unintended deamination at off-target DNA sites with high homolog

Prime Editing: One of the most important improvements in gene editing is the development of prime editing (PE). Prime editing was first described in 2019 as a more flexible and accurate genome editing method compared to traditional CRISPR–Cas9 approaches [1]. It is considered more precise and generally produces fewer unwanted changes than standard Cas9 nuclease systems or base editing (BE) methods [1,2]. Prime editing can introduce different types of small genetic changes, including base substitutions, small insertions, and small deletions. Unlike the classical CRISPR–Cas9 system, it usually does not create double-stranded DNA breaks (DSBs) and does not rely on donor DNA templates, which reduces the risk of unwanted insertions or deletions (indels) at the target site [1]. Studies have also shown that prime editing lowers the chances of off-target mutations and bystander edits compared to some earlier editing tools [2,3].

Prime editing works by using a modified Cas9 protein called Cas9 nickase (Cas9n), which is fused to a reverse transcriptase (RT) enzyme [1]. This combined Cas9n–RT complex is directed to a specific DNA sequence by a specially designed RNA molecule known as prime editing guide RNA (pegRNA). The pegRNA contains a spacer sequence that matches the target DNA. It also includes a scaffold region that allows it to interact properly with the Cas9n protein.

In addition, the pegRNA carries a reverse transcription template (RTT), which contains the exact genetic change that needs to be introduced. At the end of the pegRNA, there is a primer binding site (PBS). After Cas9n makes a single-strand nick in the DNA, the PBS binds to the exposed 3' end of the DNA strand. This allows the reverse transcriptase enzyme to copy the edited sequence from the RTT directly into the genome [1]. Through this process, prime editing introduces the desired change in a more controlled and accurate way compared to earlier genome editing methods.

Prime Editing:

RNA can also be modified instead of DNA when researchers want to avoid permanent genetic changes or reduce the risk of genomic off-target effects. One important example is the RNA-targeting Type VI CRISPR system, Cas13. Cas13 binds with

a specific CRISPR RNA (crRNA) and recognizes a complementary mRNA sequence. Once bound, Cas13 cleaves the target mRNA, which leads to reduced expression of the corresponding gene because the message required for protein production is destroyed (Abudayyeh et al., 2016; Cox et al., 2017) [56,57].

To avoid RNA cleavage, scientists have developed catalytically inactive Cas13 (dCas13). This inactive protein can be fused with enzymes such as ADAR (adenosine deaminases acting on RNA). The ADAR enzyme converts adenosine (A) into inosine (I), and inosine is read as guanine (G) by the cellular machinery, resulting in an A-to-I

change at the RNA


level (Cox et al., 2017) [57]. Similarly, other RNA base editing systems have been designed to introduce A-to-I and C-to-U conversions without cutting the RNA strand, allowing targeted and reversible RNA modifications (Abudayyeh et al., 2017) [58].

However, RNA editing has certain limitations. Since mRNA is continuously transcribed from DNA and usually has a short lifespan inside the cell, the editing system must remain active for a longer period to maintain its effect. Continuous expression of RNA-editing machinery may increase the possibility of unintended edits, including nearby bystander

changes and potential off-target activity (Cox et al., 2017) [57].

introduce A-to-I and C-to-U conversions without cutting the RNA strand, allowing targeted and reversible RNA modifications (Abudayyeh et al., 2017) [58].

However, RNA editing has certain limitations. Since mRNA is continuously transcribed from DNA and usually has a short lifespan inside the cell, the editing system must remain active for a longer period to maintain its effect. Continuous expression of RNA-editing machinery may increase the possibility of unintended edits, including nearby bystander changes and potential off-target activity (Cox et al., 2017) [57].



CONCLUSION :

Genome editing has changed a lot over the years, starting from early methods like restriction enzymes, ZFNs, and TALENs to the more advanced CRISPR-Cas systems. Among all these tools, CRISPR-Cas9 has become the most widely used because it is easier to design, more efficient, and more flexible compared to older techniques. The development of base editing and prime editing has further improved the accuracy of gene modification. These newer methods reduce unwanted DNA breaks and lower the risk of extra mutations.

In addition, RNA editing systems like Cas13 have provided another option where genes can be modified without making permanent changes in DNA. This is helpful in situations where temporary correction is needed. Improvements in delivery systems, such as viral vectors and nanoparticles, have also made gene editing more practical for medical use.

Overall, CRISPR-based technologies have opened new possibilities for treating genetic diseases and improving precision medicine. However, challenges such as safety concerns, off-target effects, delivery efficiency, and ethical issues still need careful attention. Continued research and responsible use of this technology are important to ensure



safe and effective applications in the future.

DECLARATION OF GENERATIVE AI AND AI-ASSISTED TECHNOLOGIES USED IN THE WRITING PROCESS.

During the preparation of this work, the authors used ChatGPT4 in order to improve text readability. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

REFERENCE.

1. Wong C. UK first to approve CRISPR treatment for diseases: what you need to know. *Nature*. 2023;623:676–677. <https://doi.org/10.1038/d41586-023-03500-9>
2. Jasin M. Genetic manipulation of genomes with rare-cutting endonucleases. *Trends Genet*. 1996;12:224–228. [https://doi.org/10.1016/0168-9525\(96\)10023-9](https://doi.org/10.1016/0168-9525(96)10023-9)
3. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. *Nat Rev Mol Cell Biol*. 2013;14:49–55. <https://doi.org/10.1038/nrm3486>
4. Wood AJ, Lo TW, Zeitler B, et al. Targeted genome editing across species using ZFNs and TALENs. *Science*. 2011;333:307. <https://doi.org/10.1126/science.1207773>
5. Nussenzweig PM, Marraffini LA. Molecular mechanisms of CRISPR-Cas immunity in bacteria. *Annu Rev Genet*. 2020;54:93–120. <https://doi.org/10.1146/annurev-genet-011220-102321>
6. Garneau JE, Dupuis ME, Villion M, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. *Nature*. 2010;468:67–71. <https://doi.org/10.1038/nature09523>
7. Sapranaukas R, Gasiunas G, Fremaux C, et al. The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*. *Nucleic Acids Res*. 2011;39:9275–9282. <https://doi.org/10.1093/nar/gkr606>
8. Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature*. 2011;471:602–607. <https://doi.org/10.1038/nature09886>
9. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci USA*. 2012;109:E2579–E2586. <https://doi.org/10.1073/pnas.1208507109>
10. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337:816–821. <https://doi.org/10.1126/science.1225829>
11. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. *Science*. 2013;339:823–826. <https://doi.org/10.1126/science.1232033>
12. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013;339:819–823. <https://doi.org/10.1126/science.1231143>
13. Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. *eLife*. 2013;2:e00471. <https://doi.org/10.7554/eLife.00471>
14. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nat Biotechnol*. 2013;31:230–232. <https://doi.org/10.1038/nbt.2507>
15. Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol*. 2013;31:227–229. <https://doi.org/10.1038/nbt.2501>
16. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. *Science*. 2018;361:866–869. <https://doi.org/10.1126/science.aat5011>
17. Sternberg SH, Redding S, Jinek M, et al. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature*. 2014;507:62–67. <https://doi.org/10.1038/nature13011>
18. Pacesa M, Loeff L, Querques I, et al. R-loop formation and conformational activation mechanisms of Cas9. *Nature*. 2022;609:191–196